Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shady I Tantawy

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Blood Advances|November 10, 2022
Curing CLL: one clone at a timeBurcu Aslan, Shady I Tantawy, Varsha Gandhi
Frontiers in Oncology|August 21, 2023
Targeting MCL-1 protein to treat cancer: opportunities and challengesShady I Tantawy, Natalia Timofeeva, Aloke Sarkar, et al.
Oncotarget|June 21, 2023
Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stabilityShady I Tantawy, Natalia Timofeeva, Ana Hernandez, et al.
Blood Advances|July 5, 2024
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinibBurcu Aslan, Ganiraju Manyam, Lakesla R Iles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell MalignanciesShady I Tantawy, Aloke Sarkar, Stefan Hubner, et al.
Blood Cancer Journal|October 28, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progressionShady I Tantawy, Burcu Aslan, Ganiraju Manyam, et al.
Blood Cancer Journal|May 7, 2026
Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigationsNatalia Timofeeva, Breana Herrera, Hitomi Fujiwara, et al.
Blood|October 7, 2025
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, Bastien Nguyen, Sai Prasad Desikan, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Blood Advances|November 10, 2022
Curing CLL: one clone at a timeBurcu Aslan, Shady I Tantawy, Varsha Gandhi
Frontiers in Oncology|August 21, 2023
Targeting MCL-1 protein to treat cancer: opportunities and challengesShady I Tantawy, Natalia Timofeeva, Aloke Sarkar, et al.
Oncotarget|June 21, 2023
Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stabilityShady I Tantawy, Natalia Timofeeva, Ana Hernandez, et al.
Blood Advances|July 5, 2024
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinibBurcu Aslan, Ganiraju Manyam, Lakesla R Iles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell MalignanciesShady I Tantawy, Aloke Sarkar, Stefan Hubner, et al.
Blood Cancer Journal|October 28, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progressionShady I Tantawy, Burcu Aslan, Ganiraju Manyam, et al.
Blood Cancer Journal|May 7, 2026
Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigationsNatalia Timofeeva, Breana Herrera, Hitomi Fujiwara, et al.
Blood|October 7, 2025
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, Bastien Nguyen, Sai Prasad Desikan, et al.
Pageof 1